Version 1
: Received: 4 July 2023 / Approved: 4 July 2023 / Online: 10 July 2023 (14:14:46 CEST)
How to cite:
Matsumoto, T.; Wada, H.; Shiraki, K.; Suzuki, K.; Yamashita, Y.; Tawara, I.; Shimpo, H.; Shimaoka, M. The Evaluation of the FVIII Activity and Hypercoagulability in Patients Treated With FVIII Concentrate Using a Clot Waveform Analysis. Preprints2023, 2023070392. https://doi.org/10.20944/preprints202307.0392.v1
Matsumoto, T.; Wada, H.; Shiraki, K.; Suzuki, K.; Yamashita, Y.; Tawara, I.; Shimpo, H.; Shimaoka, M. The Evaluation of the FVIII Activity and Hypercoagulability in Patients Treated With FVIII Concentrate Using a Clot Waveform Analysis. Preprints 2023, 2023070392. https://doi.org/10.20944/preprints202307.0392.v1
Matsumoto, T.; Wada, H.; Shiraki, K.; Suzuki, K.; Yamashita, Y.; Tawara, I.; Shimpo, H.; Shimaoka, M. The Evaluation of the FVIII Activity and Hypercoagulability in Patients Treated With FVIII Concentrate Using a Clot Waveform Analysis. Preprints2023, 2023070392. https://doi.org/10.20944/preprints202307.0392.v1
APA Style
Matsumoto, T., Wada, H., Shiraki, K., Suzuki, K., Yamashita, Y., Tawara, I., Shimpo, H., & Shimaoka, M. (2023). The Evaluation of the FVIII Activity and Hypercoagulability in Patients Treated With FVIII Concentrate Using a Clot Waveform Analysis. Preprints. https://doi.org/10.20944/preprints202307.0392.v1
Chicago/Turabian Style
Matsumoto, T., Hideto Shimpo and Motomu Shimaoka. 2023 "The Evaluation of the FVIII Activity and Hypercoagulability in Patients Treated With FVIII Concentrate Using a Clot Waveform Analysis" Preprints. https://doi.org/10.20944/preprints202307.0392.v1
Abstract
Background: Although the use of regular replacement therapy including emicizumab for severe hemophilia has been spread, the assessment of the hemostatic ability using routine activated partial thromboplastin time (APTT) is still difficult in patients being treated with emicizumab.
Methods: The hemostatic ability in patients treated with FVIII concentrate or emicizumab was evaluated by APTT, thrombin time (TT) and a small amount of tissue factor induced FIX activation assay (sTF/FIXa) using a clot waveform analysis (CWA).
Results: FVIII activities based on a CWA-TT were significantly higher than those based on a CWA-APTT or chromogenic assay. FVIII activities based on the three assays in plasma without emicizumab were closely correlated, and those in plasma with emicizumab based on a CWA-TT and chromogenic assays were also closely correlated. The CWA-APTT and CWA-TT showed different patterns in patients treated with FVIII concentrates from those treated with emicizumab. In particular, the CWA-TT in patients treated with FVIII concentrate showed that the peak heights were significantly higher in platelet-rich plasma than in platelet-poor plasma. In plasma with approximately 16% of FVIII activity based on APTT assay from patients treated with FVIII concentrate, the peak height on the CWA-sTF/FIXa showed a higher hemostatic abilitythan normal plasma.
Conclusions: The CWA-TT can measure the FVIII activity in patients treated with emicizumab. Although routine APTT evaluations demonstrate a low hemostatic ability in patients treated with FVIII concentrate, the CWA-TT and CWA-sTF/FIXa show hypercoagulability in those patients.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
